Although an anti-fibrosis treatment is greatly needed for humans with work-related or other musculoskeletal disorders [95], the anti-CCN2 drug used here has yet to be tested in humans for overuse-induced musculoskeletal disorders. This evidence concerns the gene CCN2 and musculoskeletal system disorder.